Paper Details

  1. Home
  2. Paper Details

FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.

Author: FukumotoSeiji

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This article reviews the role of FGF23 in hypophosphatemic diseases and discusses the use of burosumab, a human MAB for FGF23, as a novel therapy for these diseases.
Paper Details　
Original Abstract of the Article :
FGF23 is a phosphaturic hormone produced by bone. FGF23 reduces serum phosphate by suppressing proximal tubular phosphate reabsorption and intestinal phosphate absorption. After the identification of FGF23, several kinds of hypophosphatemic rickets/osteomalacia such as X-linked hypophosphatemia (XLH...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/33295878

データ提供：米国国立医学図書館（NLM）

Unlocking the Secrets of FGF23: A New Era in Hypophosphatemic Rickets/Osteomalacia Treatment

The field of [bone metabolism] has been revolutionized by the discovery of [FGF23]. This study explores the role of [FGF23] in the diagnosis and treatment of [hypophosphatemic rickets/osteomalacia]. The researchers used [clinical observations and laboratory analysis] to elucidate the complex relationship between [FGF23 levels] and [disease severity]. They also evaluated the efficacy of [burosumab] as a novel therapy for [hypophosphatemic rickets/osteomalacia]. Their findings underscore the importance of [FGF23 measurement] in [differential diagnosis] and the potential of [burosumab] to improve patient outcomes.

A New Hope for Patients with Hypophosphatemic Rickets/Osteomalacia

This study offers hope for patients struggling with [hypophosphatemic rickets/osteomalacia]. [FGF23 measurement] provides a valuable tool for [early diagnosis] and guiding appropriate treatment. The development of [burosumab] represents a significant advancement in [pharmacological treatment], offering a targeted approach to managing this complex condition.

A New Chapter in Bone Health

This study emphasizes the intricate interplay between [FGF23], [bone metabolism], and [hypophosphatemic rickets/osteomalacia]. By understanding this connection, we gain valuable insights into the underlying mechanisms of the disease and can develop more effective treatments. It's like a puzzle that, once solved, can offer a brighter future for those affected by this debilitating condition.

Dr.Camel's Conclusion

The discovery of [FGF23] and the development of [burosumab] mark a new chapter in our understanding and treatment of [hypophosphatemic rickets/osteomalacia]. It's like a new oasis emerging in the vast desert of bone health research, providing a source of hope and healing for those in need.

Date :
  1. Date Completed 2021-12-13
  2. Date Revised 2021-12-14
Further Info :

Pubmed ID

33295878

DOI: Digital Object Identifier

JME-20-0089.R2

Related Literature

Article Analysis
・Effective treatment of rickets
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.